These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35413990)

  • 1. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.
    Obinata D; Funakoshi D; Takayama K; Hara M; Niranjan B; Teng L; Lawrence MG; Taylor RA; Risbridger GP; Suzuki Y; Takahashi S; Inoue S
    Sci Rep; 2022 Apr; 12(1):6094. PubMed ID: 35413990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
    Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
    BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Receptor in Advanced Prostate Cancer.
    Takayama KI; Suzuki Y; Yamamoto S; Obinata D; Takahashi S; Inoue S
    Endocrinology; 2019 Feb; 160(2):463-472. PubMed ID: 30649323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer.
    Yamamoto S; Takayama KI; Obinata D; Fujiwara K; Ashikari D; Takahashi S; Inoue S
    Cancer Sci; 2019 Nov; 110(11):3476-3485. PubMed ID: 31454442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.
    Whitworth H; Bhadel S; Ivey M; Conaway M; Spencer A; Hernan R; Holemon H; Gioeli D
    PLoS One; 2012; 7(6):e38950. PubMed ID: 22761715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
    Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
    Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.
    Jariwala U; Cogan JP; Jia L; Frenkel B; Coetzee GA
    Prostate; 2009 Mar; 69(4):392-400. PubMed ID: 19058140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
    Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
    Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer.
    McClurg UL; Harle VJ; Nabbi A; Batalha-Pereira A; Walker S; Coffey K; Gaughan L; McCracken SR; Robson CN
    Oncotarget; 2015 Nov; 6(35):37724-36. PubMed ID: 26462181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.
    Wang J; Zhang H; Zhang X; Wang P; Wang H; Huang F; Zhou C; Zhou J; Li S
    Oncotarget; 2016 Dec; 7(49):81377-81388. PubMed ID: 27835608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT; Wilson EM; Shapiro DJ
    J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
    Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
    Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
    Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
    Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
    Nyquist MD; Ang LS; Corella A; Coleman IM; Meers MP; Christiani AJ; Pierce C; Janssens DH; Meade HE; Bose A; Brady L; Howard T; De Sarkar N; Frank SB; Dumpit RF; Dalton JT; Corey E; Plymate SR; Haffner MC; Mostaghel EA; Nelson PS
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.
    Nakka M; Agoulnik IU; Weigel NL
    Int J Biochem Cell Biol; 2013 Apr; 45(4):763-72. PubMed ID: 23270728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
    Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
    Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer.
    Obinata D; Takayama K; Urano T; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Ouchi Y; Takahashi S; Inoue S
    Int J Cancer; 2012 Mar; 130(5):1021-8. PubMed ID: 21387309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.